Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15728505 | 0.88 | MAP4K4 (0.61) | KITMAP4K4POLBCNR1CNR2 | |
| SCHEMBL31737149 | 0.87 | KIT (0.55) | KITMAP4K4POLBCNR1CNR2 | |
| SCHEMBL11359394 | 0.86 | KIT (0.52) | KITMAP4K4POLBCNR1CNR2 | |
| SCHEMBL655295 | 0.85 | KIT (0.53) | KITMAP4K4POLBCNR1CNR2 | |
| SCHEMBL23932471 | 0.85 | KIT (0.53) | KITMAP4K4POLBCNR1CNR2 | |
| SCHEMBL30042101 | 0.85 | KIT (0.53) | KITMAP4K4POLBCNR1CNR2 | |
| SCHEMBL20213014 | 0.84 | KIT (0.55) | KITMAP4K4POLBCNR1CNR2 | |
| SCHEMBL3885884 | 0.83 | KIT (0.54) | KITMAP4K4CNR1CNR2SMARCA2 | |
| SCHEMBL655402 | 0.82 | MAP4K4 (0.46) | HTTKITMAP4K4POLBCNR1 | |
| SCHEMBL20213304 | 0.82 | KIT (0.53) | KITMAP4K4CNR1CNR2SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-02-04 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | disclosed |
| EP-2923734-A1 | Purine analogues and their use as immunosuppressive agents | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| EP-2575969-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012035423-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-03-22 | — | — | WO | disclosed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | disclosed |
| EP-2405973-A2 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011147753-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010103130-A2 | NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTT 4032/4885KIT 1345/4885MAP4K4 141/4885 |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | TPMT, STAT6, IL4 | HTT 4519/4885KIT 1306/4885MAP4K4 2565/4885 |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | TPMT, STAT6, IL4 | HTT 4519/4885KIT 1306/4885MAP4K4 2565/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTT 4032/4885KIT 1345/4885MAP4K4 141/4885 |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | RNASE1, HAVCR2, RNASEH1 | HTT 1008/4885KIT 3557/4885MAP4K4 4303/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | HTT 4100/4885KIT 916/4885MAP4K4 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.